Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
March 22, 2024 at 02:47 am EDT
Share
EQS-News: Eckert & Ziegler SE
/ Key word(s): Annual Results
Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
22.03.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.
In the Medical segment, sales rose by € 24.3 million or 27% to € 115.2 million compared to the previous year. The increase in sales was driven in particular by strong demand for radiopharmaceuticals. At € 130.9 million, sales in the Isotope Products segment remained at the previous year's level (€ 131.4 million).
For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million.
The full 2023 financial statements can be found here: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz23e.pdf
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.
22.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Language:
English
Company:
Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone:
+49 30 941084-138
Fax:
+49 30 941084-0
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Indices:
SDAX, TecDax,
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.